PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 12138052. This proceeding, IPR2026-00097, resulted in a discretionary denial of institution, meaning no claims were challenged on the merits in a full trial. This outcome generally strengthens the patent owner's position as the claims have not been subjected to a full IPR proceeding.

IPR2026-00097 — Magnolia Medical Technologies, Inc. v. Kurin Inc

• Type: Inter Partes Review
• Filed: 2025-11-12
• Status: Discretionary Denial. The petition for inter partes review was denied institution on discretionary grounds, meaning the PTAB chose not to initiate a full review of the challenged claims.
• Judge panel: Administrative Patent Judges Jennifer L. Barry, David C. McKone, and Jeffrey P. reminiscently (remitted).
• Petition grounds: Magnolia Medical Technologies, Inc. challenged claims 1-20 of U.S. Patent No. 12,138,052 as unpatentable under 35 U.S.C. § 103 over U.S. Patent Publication No. 2017/0265749 (Kurin) in view of U.S. Patent Publication No. 2014/0350495 (Yoon).
• Institution decision: Denied on 2026-05-14. The PTAB exercised its discretion to deny institution under 35 U.S.C. § 314(a) considering the Fintiv factors, primarily weighing factors 2, 4, 5, and 6. The Board found that a parallel district court proceeding involving the same parties, patent, and claims was already at a more advanced stage, with a trial scheduled for February 2027.
• Final Written Decision: Not applicable; institution was denied.
• Settlement / termination: Not applicable; institution was denied.
• Appeal: Information regarding an appeal of the discretionary denial to the Federal Circuit is not available in the provided PTAB record.
• Defensive value: The discretionary denial means the claims were not substantively reviewed, leaving them unchallenged through this IPR. For a defendant, this means the claims of US12138052 have not been narrowed or canceled by this proceeding, and an IPR challenge based on the same prior art and grounds as presented in IPR2026-00097 would likely face similar discretionary denial challenges.

Strategic summary

All claims (1-20) of US12138052 are currently sustained and untested by an IPR Final Written Decision. The sole IPR proceeding, IPR2026-00097, was denied institution on discretionary grounds under the Fintiv factors, specifically due to a co-pending district court litigation involving the same patent and parties. This denial means the merits of the obviousness challenge against claims 1-20 over the Kurin and Yoon prior art were never fully adjudicated by the PTAB.

The estoppel landscape under § 315(e)(2) for this patent is currently limited. Since the IPR was denied institution, the petitioner (Magnolia Medical Technologies, Inc.) and its privies are not estopped from raising any grounds that could have been raised in the petition, only those actually raised and instituted. However, the PTAB's reasoning for discretionary denial, particularly the advanced stage of parallel district court litigation, suggests that future IPR petitions challenging the same claims by the same parties might face similar discretionary denials. For other defendants, the specific grounds and art (Kurin and Yoon) challenged in IPR2026-00097 are still technically available for an IPR petition, but the Fintiv precedent may pose a significant hurdle if parallel litigation exists.

The proceeding signals a proactive defense strategy by the patent owner, Kurin Inc., leveraging parallel litigation to achieve discretionary denial at the PTAB. The fact that only one IPR has been filed, and it was denied institution, indicates that the patent has not yet been significantly challenged or narrowed through AIA trials.

Recommended next steps

If you are a defendant facing assertion of US12138052, it is important to review the PTAB's decision in IPR2026-00097 carefully to understand the specific reasons for the discretionary denial and whether those factors apply to your situation. The "Decision Denying Institution of Inter Partes Review" for IPR2026-00097 is available on the USPTO PTAB Decisions portal.

Specifically, assess the stage of any parallel district court litigation you might be involved in with Kurin Inc. concerning US12138052. The PTAB's emphasis on the advanced stage of the district court case (trial scheduled for February 2027) was central to its Fintiv analysis. Any new IPR petition should consider how it might be distinguishable from IPR2026-00097 to avoid a similar discretionary denial, perhaps by coordinating with the district court to seek a stay or by filing the petition much earlier in the litigation timeline.

Given that all claims remain untested by a Final Written Decision, a new IPR might be considered if strong prior art exists that was not presented in IPR2026-00097, or if the Fintiv factors can be demonstrably mitigated.

No active proceedings are currently pending that have been instituted. The institution decision for IPR2026-00097 was issued on 2026-05-14, which falls within the typical six-month statutory deadline from the filing date for institution decisions.

The absence of successful PTAB activity against this patent means its claims are currently robust from an IPR perspective.